



ANNUAL GENERAL MEETING 2018

CHAIRMAN'S ADDRESS

The 2018 fiscal year was a period of significant development and change. The Company took stock of its past activities and achievements, made plans for the future and set about pursuing the objectives identified in those plans.

It started with a detailed strategic review which commenced in September 2017 and follow up sessions now occur on a regular basis. The strategic objectives of the company were clearly identified and agreed by the Phylogica team.

This informed future operations which became focused and targeted at achieving the key objectives. And to use Phylogica's human capital to the best effect, it was decided to direct resources to the pursuit of those strategic objectives in preference to negotiating relatively small co-development deals. For while these offered the prospect of near-term cash funding, usually they did not offer development of the company's science in the key areas of focus. At this stage the priority for the team is the development of our science.

To provide the company with the necessary financial resources to support its activities, further capital was raised both during the 2018 year and since.

Shareholder approval for a portion of the latest capital raising is being sought at this meeting.

So, in summary the company has:

- Clearly identified a strategic development plan;
- A talented and motivated team focused upon achieving key objectives identified in that plan; and
- Sufficient cash resources to fund the next phase of scientific development.

During 2018, changes occurred to both the senior management and the Board of the Company. Those of us who took up positions with Phylogica during the year

acknowledge the work of our predecessors. It is now up to us to steer Phylogica through the next phase of its development.

During the next 12 months we will learn the results of the exciting work that is being performed today. My colleague Rohan Hocking will present a summary of that work later. It is my view that this period may well prove to be the most exciting phase of this Company's development to date.

A future of opportunities beckons and it is our role to capitalise upon that potential and work towards getting the value of the Company recognised in the broader market. This is another key area of focus for the Board.

I am fortunate to have joined a dedicated and talented team working in a key area of scientific development. And it is also an area where interest is growing worldwide. I look forward to continuing to contribute towards the drive to achieve success for Phylogica.

Alan Tribe

Chairman

About Phylogica

Phylogica Limited (ASX: PYC) is a biotech company focused on commercialising its intracellular drug delivery platform and screening its peptide libraries to identify drug cargoes for development against a wide range of disease targets. Phylogica controls access to the world's most structurally diverse source of peptides which have the ability to act as effective drug delivery agents and drug cargoes, penetrating cell walls to reach previously 'undruggable' targets across a range of disease types. Phylogica's platform of proprietary cell penetrating peptides has been validated across multiple animal models for the ability to deliver a diverse range of drug cargoes into cells. The company has collaborations with several pharmaceutical companies including Roche, Medimmune, Pfizer, Janssen and Genentech.

Tel: +61 8 9384 3284 | Fax: +61 8 9284 3801

www.phylogica.com

Phylogica Ltd

Results of Annual General Meeting

PERTH, Australia, 16th November 2018: Phylogica Limited (ASX:PYC) (Phylogica or the Company), pursuant to ASX Listing Rule 3.12.2, advises that all resolutions contained in the Notice of Meeting dated 26 September 2018 and put to shareholders at the Company's 2018 Annual General Meeting today were all passed unanimously on a show of hands.

In accordance with Section 251AA(1) of the Corporations Act, set out below are the total number of proxies which were received in respect of each resolution.

RESOLUTION TITLE	FOR	AGAINST	OPEN	ABSTAIN / EXCLUDED
1. Remuneration Report	511,104,316	5,967,736	13,935,247	750,275,586
2. Election - Sahm Nasser	1,261,974,498	4,681,473	13,935,247	691,667
3. Election - Alan Tribe	830,344,126	437,265	15,735,247	434,766,247
4. Re-election - Bernard Hockings	948,405,738	4,481,015	13,935,247	314,460,885
5. Ratification of Share Placement	1,233,733,248	2,917,723	9,501,913	35,130,001
6. Participation in Placement - A Tribe	828,437,459	1,297,265	15,565,247	435,982,914
7. Participation in Placement - B Hockings	946,499,071	5,141,015	13,965,247	315,677,552
8. Potential Termination Benefit - R Hockings	944,551,904	7,054,182	14,365,247	315,311,552
9. Issue Options - R Hockings	945,542,298	6,033,788	13,965,247	315,741,552

Yours faithfully

Kevin Hart

Company Secretary

ENDS